These findings strongly indicate that the mTOR signaling network in the PTEN-null tumor is independent of Akt activity and that both Akt and mTOR downstream signaling pathways play a part in PTEN-deficient prostate tumors. This evidence concerns the gene AKT1 and prostate neoplasm.